• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP- Kids' COVID syndrome—MIS-C—less severe in Omicron

Lance

MPH, CSP & CIT Retired, CHMM Emeritus
https://www.cidrap.umn.edu/news-perspective/2022/05/kids-covid-syndrome-mis-c-less-severe-omicron


Kids' COVID syndrome—MIS-C—less severe in Omicron


Filed Under:
COVID-19
Mary Van Beusekom | News Writer | CIDRAP News

May 23, 2022

COVID-19–related multisystem inflammatory syndrome in children (MIS-C) was milder amid the Omicron variant surge than during the Alpha and Delta waves in Israel, concludes a research letter published late last week in JAMA.

Researchers from Rambam Health Care Campus in Haifa conducted prospectively studied all pediatric MIS-C patients at 12 Israeli hospitals during the same 16-week period in the Alpha (Dec 20, 2020, to Apr 10, 2021), Delta (Jul 18 to Nov 13, 2021), and Omicron (Nov 21, 2021, to Mar 12, 2022) pandemic waves. Participating hospitals account for roughly 70% of pediatric intensive care unit (ICU) admissions in Israel.

Of the 171 MIS-C patients, 59 (34.5%) were diagnosed during the Alpha wave, while 79 (46.2%) were identified during Delta, and 33 (19.3%) amid Omicron. Median patient age was 8 years, and 55% were boys.

Five of 79 patients (6.3%) in the Delta wave and 5 of 33 (15.1%) during Omicron had received a second COVID-19 vaccine dose at least 2 weeks before hospitalization. (Vaccination wasn't widely available in the Alpha wave.) No vaccinated patients required ICU care or treatment with vasopressors to raise their blood pressure.

Better cardiac outcomes, fewer ICU stays


Cardiac outcomes were better during the Omicron wave, and there were fewer ICU admissions (7 [21.2%]) than during Delta (39 [49.4%]) and Alpha (34 [57.6%]). Median hospital stay was also 2 days shorter amid Omicron than in previous waves.

Fewer patients required vasopressors during the Omicron surge (6.0%) than in Alpha (22%) and Delta (17.7%). Likewise, no patients needed mechanical ventilation amid Omicron, versus 8.5% in the Alpha period and 8.9% in Delta. One patient died in the Delta era.

Nationwide, 188,800 pediatric patients were diagnosed as having COVID-19, and 103 had MIS-C during the Alpha wave, while 233,585 had COVID-19 and 115 had MIS-C amid Delta, and 945,779 and 36 had COVID-19 and MIS-C, respectively, during Omicron.

The incidence of MIS-C per 100,000 children was 54.5 during the Alpha wave, 49.2 amid Delta, and 3.8 in the Omicron era. Compared with the Omicron period, the incidence of MIS-C was 14.3 times higher amid Alpha and 12.9 times higher during Delta.

The lesser severity and incidence of MIS-C during the Omicron wave relative to the Alpha and Delta periods may be explained by the nature of the Omicron variant itself, previous COVID-19 infections, vaccination, and the refinement of treatment methods since the pandemic began, the study authors said.

"A 2022 study from South Africa on the Omicron wave reported no cases of MIS-C, a finding that corroborates these results," they wrote.

Study limitations included the small sample size and single-country data, the researchers said. "Because MIS-C is a late-onset phenomenon of SARS-CoV-2 infection, cases that appeared after the 16-week period of each wave were not included," they concluded.
 
Back
Top Bottom